Drug Profile
MG 1102
Alternative Names: Greenstatin; MG1102; Recombinant anti-angiogenic protein - GC Pharma; Recombinant human apolipoprotein (a) Kringle V; rhLK8Latest Information Update: 07 Feb 2018
Price :
$50
*
At a glance
- Originator Green Cross
- Developer GC Biopharma
- Class Antineoplastics; Apolipoprotein therapeutics; Gene therapies; Recombinant proteins
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in South Korea (IV, Infusion)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)
- 12 Mar 2013 Green Cross completes enrolment in its phase I trial for Solid tumours in USA & South Korea (NCT01809912)